Recent Research Trends in Zika Virus Treatment and Vaccines
Zika Virus, a Threat to the Nervous System with No Available Treatment
Zika virus is known for its neurovirulence, causing Guillain-Barré syndrome in adults and congenital birth defects in neonates. Despite the large-scale outbreak in 2015-16, there is still no approved treatment, making it a significant challenge for global health.
Repurposed Drugs and Vaccines, a Multi-Faceted Attack
Research teams have tested repurposed drugs such as niclosamide, favipiravir, and chloroquine, which interfere with viral proteins, host cell kinases, glucose transporters, and NMDA receptors. Meanwhile, viral vaccine candidates like VRC-ZKADNA090-00-VP, AGS-v, and mRNA-1325 have shown safety and immunogenicity in early clinical trials.
CRISPR-Cas13b, a New Line of Defense through RNA Cleavage
CRISPR-Cas13b-based genome editing technology has successfully cleaved Zika virus ssRNA in infected cells, inhibiting viral replication. This approach offers a novel mechanism distinct from traditional drug approaches, with innovative potential for future treatment development.
Future Implications and Prospects
If ongoing clinical trials and gene editing research thoroughly verify the safety of these treatments for pregnant women and fetuses, practical treatments and preventive vaccines may soon emerge. This would provide a foundation for effectively responding to future Zika virus outbreaks.
Zika virus has been a significant cause of neurovirulence in humans, posing a global health concern due to its association with Guillain-Barré syndrome in adults and congenital birth defects in neonates. Despite its re-emergence in the 2015-16 outbreaks, there is no approved treatment for Zika virus infection to date, making it a pressing concern. Recent efforts in drug repurposing and viral vaccine development offer a promising roadmap to mitigate Zika virus infections. Investigational molecules commonly target viral proteins, protein precursors, and complexes, and interfere with host pathways involving cellular kinases, glucose transporters, and NMDA receptors. Repurposed drug candidates like niclosamide, favipiravir, and chloroquine exhibit promising antiviral potential. In parallel, anti-ZIKV vaccines like VRC-ZKADNA090-00-VP, AGS-v, and mRNA-1325 have progressed to early-phase clinical trials, achieving acceptable safety and immunogenic profiles. CRISPR-Cas13b-based genome editing has also been successfully demonstrated to cleave Zika virus ssRNA in infected cells. This review elucidates the pathogenesis of Zika virus infection and provides an in-depth overview of current strategies and research aimed at targeting host and viral factors to achieve successful therapeutic outcomes. The review also underscores the importance of safety evaluation of developmental drugs in pregnancy due to the strong association between ZIKV and fetal birth defects.
The goal is to address the life-threatening congenital birth defects caused by Zika virus in pregnant women and neonates. With new treatments and safe vaccines, our families and society as a whole can be freed from this risk.